Phase 1 Study of SAR445877 for Metastatic Colorectal Cancer
This study is testing a new combination of medicines for people with metastatic colorectal cancer that is microsatellite stable (MSS). Researchers want to see if SAR445877, when given with FOLFOX6 and bevacizumab, is safe and tolerable as a first treatment. The main goal is to find the safest dose of SAR445877 in this combination. This study is open to adults aged 18 and older who are willing to follow the study plan. The study is currently unclear on its recruitment status and plans to enroll 41 participants. Success will be measured by how safe the treatment is and any side effects experienced.
- Study design
- This is a Phase 1 interventional study, meaning it's an early-stage trial focused on safety. It plans to enroll 41 participants.
- What's involved
- You would need to understand and sign an informed consent form, and be willing to attend scheduled visits, follow treatment plans, and complete laboratory tests and other study procedures.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Aung Naing, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0